Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
A serious adverse effect of cancer therapies is cardiovascular toxicity, which significantly limits the widespread use of antineoplastic agents. The promising new field of cardio-oncology offers the identification of potent anti-cancer therapeutics that effectively inhibit cancer cell proliferation...
Main Authors: | Zoltán Szabó, Lilla Hornyák, Márton Miskei, Lóránt Székvölgyi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.569955/full |
Similar Items
-
Cardiotoxicity of Anticancer Therapeutics
by: Jerry Dong, et al.
Published: (2018-02-01) -
Targeting KRAS in Cancer: Promising Therapeutic Strategies
by: Lisa Maria Mustachio, et al.
Published: (2021-03-01) -
Histone H3 Lysine 56 Acetylation Is Required for Formation of Normal Levels of Meiotic DNA Breaks in S. cerevisiae
by: Zsolt Karányi, et al.
Published: (2020-01-01) -
Magnesium sulfate protects the heart against carbon monoxide-induced cardiotoxicity in rats
by: Kaveh Tabrizian, et al.
Published: (2018-01-01) -
DiOHF Protects Against Doxorubicin-Induced Cardiotoxicity Through ERK1 Signaling Pathway
by: Danqi Chang, et al.
Published: (2019-09-01)